SRRA Sierra Oncology Inc.

1.45
+0.04  (+3%)
Previous Close 1.41
Open 1.43
Price To Book 1.29
Market Cap 108298010
Shares 74,688,283
Volume 157,736
Short Ratio
Av. Daily Volume 363,996

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Discontinued following poor efficacy - June 2016
PNT2258
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - cancer
Development suspended - June 2016
PNT2258
Richter's Transformation
Phase 1/2 preliminary data due at ASCO June 1, 2019. 8am CT.
SRA737
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Phase 1/2 preliminary data due at ASCO June 1, 2019. 8am.
SRA737 + Low-Dose Gemcitabine
Solid Tumors
Phase 2 presentation at ASH 2018 noted 44% transfusion free for at least 12 weeks.
Momelotinib
Myelofibrosis